Clinical trial NCT00731328: Donor Stem Cell Transplant After Busulfan, Fludarabine, Methylprednisolone, and Antithymocyte Globulin in Treating Patients With Bone Marrow Failure Syndrome
Official title: HLA-HAPLOIDENTICAL FAMILIAL DONOR HEMATOPOIETIC CELL TRANSPLANTATION AFTER REDUCED INTENSITY CONDITIONING OF BUSULFAN, FLUDARABINE, AND ANTI-THYMOCYTE GLOBULIN FOR PATIENTS WITH BONE MARROW FAILURE SYNDROME - A PHASE 2 STUDY
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Leukemia
Myelodysplastic Syndromes
Nonmalignant Neoplasm
Paroxysmal Nocturnal Hemoglobinuria
Keywords: refractory anemia
refractory anemia with ringed sideroblasts
refractory cytopenia with multilineage dysplasia
childhood myelodysplastic syndromes
de novo myelodysplastic syndromes
previously treated myelodysplastic syndromes
secondary myelodysplastic syndromes
aplastic anemia
paroxysmal nocturnal hemoglobinuria
Lead sponsor: Asan Medical Center
Sponsor class: OTHER
First posted: 2008-08-11
Enrollment: 15
Sex: ALL
Maximum age (years): 75
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: RATIONALE: Giving low doses of chemotherapy and antithymocyte globulin before a donor stem cell transplant helps stop the growth of abnormal cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining abnormal cells (graft-versus-tumor effect).

PURPOSE: This phase II trial is studying how well a donor stem cell transplant works after busulfan, fludarabine, methylprednisolone, and antithymocyte globulin in treating patients with bone marrow failure syndrome.

Detailed description: OBJECTIVES:

* To evaluate the efficacy of HLA-haploidentical familial donor hematopoietic stem cell transplantation after reduced-intensity conditioning regimen comprising busulfan, fludarabine phosphate, and anti-thymocyte globulin in patients with bone marrow failure syndromes.

OUTLINE:

* Reduced-intensity conditioning regimen: Patients receive busulfan IV daily on days -7 and -6, fludarabine phosphate IV over 30 minutes on days -7 to -2, anti-thymocyte globulin (ATG) IV over 4 hours on days -4 to -1, and methylprednisolone IV over 30 minutes starting 30 minutes before ATG on days -4 to -1.
* HLA-haploidentical donor hematopoietic stem cell transplantation: Patients receive donor hematopoietic stem cells via Hickman catheter over 1 hour on days 0 or 1.
* Graft-versus-host-disease prophylaxis (GVHD): Patients receive cyclosporine IV over 2-4 hours every 12 hours starting on day -1 (cyclosporine can be given orally once oral medication can be tolerated) and methotrexate IV on days 2, 4 , 7, and 12. In the absence of GVHD, cyclosporine is tapered starting between days 30 to 60.

After completion of study treatment, patients are followed periodically for 1 year.

Eligibility criteria: DISEASE CHARACTERISTICS:

* Diagnosis of any of the following bone marrow failure syndromes:

  * Severe aplastic anemia, meeting 1 of the following criteria:

    * Not responsive to immunosuppressive therapy
    * With recurrent cytopenia after immunosuppressive therapy or allogeneic hematopoietic cell transplantation
  * Low-risk myelodysplastic syndrome, including any of the following:

    * Refractory anemia
    * Refractory anemia with ringed sideroblasts
    * Refractory cytopenia with multi-lineage dysplasia
  * Paroxysmal nocturnal hemoglobinuria, meeting 1 of the following criteria:

    * With thrombotic episodes
    * With severe cytopenia
* No willing, suitable HLA-compatible donor in family or in donor registries

  * Related donor with HLA-haploidentical mismatch at three or less of 6 loci
  * Patients with very severe neutropenia (\< 200/μL) or febrile episodes, who feel urgent need for allogeneic hematopoietic cell transplantation, are eligible without a search for HLA-matched unrelated donors

PATIENT CHARACTERISTICS:

* Karnofsky performance status 70-100%
* Bilirubin \< 2.0 mg/dL
* AST \< 3 times upper limit of normal
* Creatinine \< 2.0 mg/dL
* Ejection fraction \> 40% by MUGA scan

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics

Primary outcomes:
measure: Donor cell engraftment
timeFrame: 10-35 days after transplantation
Secondary outcomes:
measure: Regimen-related toxicities as assessed by NCI's Common Toxicity Criteria
timeFrame: 0-60 months after transplantation
measure: Acute and chronic GVHD
timeFrame: 15-100 days; 100 days to 4 years
measure: overall survival
timeFrame: 0-60 months
measure: event-free survival
timeFrame: 0-60 months after transplatation
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center - University of Ulsan College of Medicine
Study officials:
affiliation: Asan Medical Center
name: Kyoo H. Lee, MD
role: PRINCIPAL_INVESTIGATOR
References: